IBI-363
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for IBI-363, covering 2025-09-30 to 2026-02-13. Get the full timeline:
Most recent: Clinical Trial Update: IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer [Phase 2]